Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer

The patient-derived organoids (PDO) platform recapitulates the phenotype, genotype, and molecular characteristics of primary tumors. High-throughput drug screening in terms of pharmacotyping using standard-of-care chemotherapy agents in the PDO platform has shown promising sensitivities to guide pre...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cancer research 2022-08, Vol.28 (15), p.3176-3178
Main Authors:	Zhang, Yuqing, Houchen, Courtney W, Li, Min
Format:	Article
Language:	eng
Subjects:	Biomarkers Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - genetics Carcinoma, Pancreatic Ductal - pathology Humans Organoids - pathology Pancreatic Neoplasms Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - genetics Pancreatic Neoplasms - pathology Precision Medicine
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The patient-derived organoids (PDO) platform recapitulates the phenotype, genotype, and molecular characteristics of primary tumors. High-throughput drug screening in terms of pharmacotyping using standard-of-care chemotherapy agents in the PDO platform has shown promising sensitivities to guide precision medicine for individual patients with pancreatic ductal adenocarcinoma (PDAC) within a clinically relevant time frame. See related article by Seppälä et al., p. 3296.
ISSN:	1078-0432 1557-3265